MT-2766 not checked

Medicago · AS03 adjuvant

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Subjects will receive two doses of MT-2766 high dose (3.75 µg) given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)”In the company’s words, NCT05065619 on ClinicalTrials.gov
Tested for
SARS-CoV-2 Infection
Main trialPhase 1/2
“The objective of this study is to evaluate the safety and immunogenicity of MT-2766 in Japanese adults.”In the company’s words, NCT05065619 on ClinicalTrials.gov
Other names
CoVLP · AS03 adjuvant

Other drugs for SARS-CoV-2 Infection

All 43 drugs for SARS-CoV-2 Infection

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1/2Terminated 12 Mar 2022 Safety Immunogenicity Study of MT-2766 in Japanese Adults(COVID-19)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow MT-2766

Following is part of Solo: you see every change to MT-2766 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in